**Abstract**

Coronavirus disease 2019 (COVID-19) is a major issue of our times. Many aspects and features of this new and complex disease are being described on a daily basis. Major endpoints are systemic inflammation, markedly characterized by the cytokine storm, respiratory failure, and coagulation disorders, such as thrombophilia. In its terms, thrombophilia has a major impact on the COVID-19 prognosis. With regard to this, paying attention on molecular variants, such as DNA polymorphisms, epigenetic factors, and other biomarkers, could be an important approach to optimizing and personalizing the treatment of patients according to their inherited thrombotic features. This chapter brings an overview on the three major DNA polymorphisms associated with thrombophilia and proposes that these same biomarkers could be used in pretreatment screenings of patients with COVID-19 to seek the most appropriate therapy for each individual molecular profile.

**Keywords:** COVID-19, coagulation, thrombophilia, biomarkers, DNA polymorphisms
